行情

CLSN

CLSN

克莱瑞恩
NASDAQ

实时行情|Nasdaq Last Sale

0.8700
-0.0300
-3.33%
盘后: 0.8805 +0.0105 +1.21% 17:58 01/15 EST
开盘
0.9000
昨收
0.9000
最高
0.9199
最低
0.8540
成交量
303.06万
成交额
--
52周最高
6.50
52周最低
0.4305
市值
3,255.34万
市盈率(TTM)
-1.1888
分时
5日
1月
3月
1年
5年
新闻
财报
公告
公司事件
分析
简况
Celsion: Q3 Earnings Insights
Shares of Celsion (NASDAQ:CLSN) remained unaffected after the company reported Q3 results.Quarterly Results Earnings per share increased 32.00% over the past year to ($0.17), which missed the estimate of ($0.13).Revenue of $125,000 unchanged by 0.00% year over year, which beat the estimate of $80,000.Outlook Earnings guidance hasn't been issued by the company for now.Celsion hasn't issued any revenue guidance for the time being.Details Of The Call Date: Nov 16, 2020View more earnings on CLSNTime: 11:00 AMET Webcast URL: https://edge.media-server.com/mmc/p/n6e4r5nwPrice Action Company's 52-week high was at $6.5052-week low: $0.43Price action over last quarter: down 51.53%Company Overview Celsion Corp is active in the biotechnology market. The company acts as a drug developer with product candidates like ThermoDox, a heat-activated liposomal encapsulation of doxorubicin. It is in Phase III clinical trial for the treatment of primary liver cancer and a Phase II clinical trial for the treatment of recurrent chest wall breast cancer. Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers.See more from Benzinga * Click here for options trades from Benzinga * Earnings Scheduled For November 16, 2020 * Stocks That Hit 52-Week Lows On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga · 2020/11/16 13:44
Celsion Q3 Adj. EPS $(0.17) Misses $(0.13) Estimate, Sales $125.00K Beat $80.00K Estimate
Celsion (NASDAQ:CLSN) reported quarterly losses of $(0.17) per share which missed the analyst consensus estimate of $(0.13) by 30.77 percent. This is a 32 percent increase over losses of $(0.25) per share from the same
Benzinga · 2020/11/16 13:33
The Week Ahead In Biotech: The Vaccine Updates, Drug Presentations, And FDA Decisions That Will Move The Markets
Biotech stocks advanced in the week ended Nov. 13 amid a vaccine news flow-induced rally that also lifted the broader market.
Benzinga · 2020/11/15 15:14
ROSEN提醒Celsion……
美国商业资讯中文版 · 2020/11/12 09:40
Celsion Corporation to Hold Third Quarter 2020 Financial Results and Business Update Conference Call on Monday, November 16, 2020
finviz · 2020/11/09 12:30
Celsion Corporation Issues Letter To Stockholders
CEO Provides Updates on Phase III OPTIMA Study Data Analysis and ThermoDox® Investigator-Sponsored Studies   LAWRENCEVILLE, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Celsion
Benzinga · 2020/10/12 12:06
Celsion Corporation Restructures Strategic Loan Facility
ompletes New $5 Million Loan Agreement with Market Competitive Terms and Debt Reduction Consistent with Celsion's Capitalization New Agreement Ensures A Strong Balance Sheet and Additional Operating
Benzinga · 2020/09/02 12:07
Celsion: Q2 Earnings Insights
Benzinga · 2020/08/14 13:48
更多
财务预测
每股收益每股净资产每股现金流
实际值(美元)
预测值(美元)
利润表更多
净利润营业总收入营业利润
净利润(美元)
同比(%)
资产负债表更多
总资产(美元)
总负债(美元)
资产负债率(%)
现金流表更多
经营现金流投资现金流筹资现金流
经营现金流(美元)
同比(%)
了解CLSN最新的财务预测,通过CLSN每股收益,每股净资产,每股现金流等数据分析克莱瑞恩近期的经营情况,然后做出明智的投资选择。
分析师评级

2位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测
分析师预测CLSN价格均价为4.000,最高价位5.00,最低价为3.000。
EPS
机构持股
总机构数: 60
机构持股: 516.93万
持股比例: 13.82%
总股本: 3,741.77万
类型机构数股数
增持
12
158.29万
建仓
17
25.41万
减持
8
79.73万
平仓
0
0
  • 业绩
  • 资产分布
  • 分红历史
暂无数据
所属板块
生物技术和医学研究
-0.34%
制药与医学研究
+0.21%
高管信息
Chief Financial Officer/Senior Vice President/Secretary/IR Contact Officer
Jeffrey Church
Executive Vice President
Khursheed Anwer
Senior Vice President
Nicholas Borys
Director/Chief Executive Officer/President/Chairman
Michael Tardugno
Independent Director
Donald Braun
Independent Director
Pok Yu Chow
Independent Director
Frederick Fritz
Independent Director
Robert Hooper
Independent Director
Andreas Voss
  • 分红
  • 拆股
  • 内部人交易
暂无数据
注册即可获得3个月
免费美股Level2深度行情
(Nasdaq Totalview)
立即领取
CLSN 简况
Celsion Corporation是一家肿瘤药物开发公司。该公司的候选产品是ThermoDox,一种热激活脂质体封装阿霉素,ThermoDox处于治疗原发性肝癌的第三阶段临床试验(OPTIMA研究),并处于治疗复发性胸壁乳腺癌的第二阶段临床试验(DIGNITY研究)。该公司的产品还包括GEN-1,一种用于局部治疗卵巢癌与脑癌的脱氧核糖核酸(DNA)介导的免疫治疗。该公司拥有三种用于开发治疗恶性肿瘤疗法的平台技术:一种通过已知治疗方法靶向疾病的温和热敏脂质体剂型Lysolipid Thermally Sensitive Liposomes、针对治疗性质粒局部转染的核酸治疗剂TheraPlas以及肺导向抗癌核糖核酸(RNA)全身剂型TheraSilence。
展开
热门股票
代码
价格
涨跌幅

微牛提供Celsion Corporation(NASDAQ-CLSN)的股票价格、实时市场报价、专业分析师评级、深度图表和免费的CLSN股票新闻,以帮助您做出投资决策。

模拟交易:模拟炒股免费实操交易技能。您可用虚拟资金在真实市场环境中零成本、零风险体验交易CLSN股票基本功能。